Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 3, 2017, Pages e137-e138

  Kanameishi, S ^a   Dainichi, T ^a   Endo, Y ^a   Otsuka, A ^a   Tanioka, M ^a   Kabashima, K ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; EOSIN; HEMATOXYLIN; INFLIXIMAB; METHOTREXATE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE DISEASE; AGED; ALOPECIA AREATA; CASE REPORT; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HAIR FOLLICLE; HAIR GROWTH; HAIR LOSS; HAIR REGROWTH; HUMAN; LABORATORY TEST; LETTER; LOTION; LYMPHOCYTIC INFILTRATION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SKIN BIOPSY; TOPICAL TREATMENT; TREATMENT DURATION; COMPLICATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HAIR; ORAL DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ALOPECIA AREATA; ARTHRITIS, RHEUMATOID; FEMALE; HAIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 85015024175     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13879     Document Type: Letter

References (10)

1. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol 2014; 134: 1141–1142.
2. Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 2006; 5: 64–69.
3. Gilhar A, Etzioni A, Paus R. Alopecia Areata. N Engl J Med 2012; 366: 1515–1525.
4. Petukhova L, Duvic M, Hordinsky M et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466: 113–117.
5. Xing L, Dai Z, Jabbari A et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043–1049.
6. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 2012; 166: 916–926.
7. Kim TJ, Kim N, Kang HJ et al. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol 2010; 88: 1089–1097.
8. Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology—pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. SKINmed 2008; 7: 27–30.
9. Freyschmidt-Paul P, Ziegler A, McElwee KJ et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001; 11: 405–409.
10. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52: 138–139.